Bluejay Diagnostics, Inc. Share Price

Equities

BJDX

US0956333019

Biotechnology & Medical Research

Market Closed - Nasdaq 21:30:01 03/05/2024 BST 5-day change 1st Jan Change
0.547 USD +3.21% Intraday chart for Bluejay Diagnostics, Inc. -14.78% -55.16%
Sales 2022 0.25 19.85 Sales 2023 - Capitalization 1.51M 120M
Net income 2022 -9M -717M Net income 2023 -9M -717M EV / Sales 2022 -7,813,548 x
Net cash position 2022 9.6M 765M Net cash position 2023 1.84M 147M EV / Sales 2023 -
P/E ratio 2022
-0.82 x
P/E ratio 2023
-0.13 x
Employees 10
Yield 2022 *
-
Yield 2023
-
Free-Float 83.22%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.21%
1 week-14.78%
Current month+11.63%
1 month-22.69%
3 months-29.87%
6 months-85.10%
Current year-55.16%
More quotes
1 week
0.39
Extreme 0.39
0.66
1 month
0.39
Extreme 0.39
0.72
Current year
0.39
Extreme 0.39
1.22
1 year
0.39
Extreme 0.39
13.98
3 years
0.39
Extreme 0.39
125.00
5 years
0.39
Extreme 0.39
125.00
10 years
0.39
Extreme 0.39
125.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 31/12/14
Founder 52 31/12/14
Chief Administrative Officer - -
Members of the board TitleAgeSince
Director/Board Member 77 30/04/21
Director/Board Member 77 31/12/16
Director/Board Member 59 14/11/21
More insiders
Date Price Change Volume
03/05/24 0.547 +3.21% 20,872
02/05/24 0.53 -1.12% 66,447
01/05/24 0.536 +9.39% 81,970
30/04/24 0.49 -11.60% 89,933
29/04/24 0.5543 -13.65% 252,176

Delayed Quote Nasdaq, May 03, 2024 at 09:30 pm

More quotes
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a rapid, near-patient testing system for triage and monitoring of disease progression. Its product candidate, an IL-6 Test for sepsis triage, is designed to provide results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and better triage/treatment decisions. The Symphony platform is a combination of its intellectual property (IP) and exclusively licensed and patented IP that consists of a mobile device and single-use test cartridges. The Symphony platform and its initial biomarker test, Symphony IL-6 test, is suited to address a subset of the global in vitro diagnostics devices market, including sepsis, cardio-metabolic diseases, cancer and other diseases that require rapid tests. Symphony targets critical care markets where physicians must quickly determine patient acuity to identify optimal treatment regimens.
Calendar
More about the company